Article info
PDFOriginal Articles
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)
- Address correspondence and reprint requests to: David S. Alberts, MD, Arizona Cancer Center, University of Arizona, Box 245024, 1515 North Campbell Avenue, Tucson, AZ 85724-5024, USA. Email: dalberts{at}azcc.arizona.edu; Southwest Oncology Group (SO211), Operations Office, 14980 Omicron Drive, San Antonio, TX 78245-3217, USA.
Citation
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)
Publication history
- First published July 1, 2007.
Online issue publication
December 03, 2018
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2007, IGCS and ESGO